Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Everolimus
Drug ID BADD_D00858
Description Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Indications and Usage Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
Marketing Status Prescription
ATC Code L01EG02; L04AA18
DrugBank ID DB01590
KEGG ID D02714
MeSH ID D000068338
PubChem ID 6442177
TTD Drug ID D0K3QS
NDC Product Code 65727-064; 65129-1324; 0078-0626; 0078-0620; 0054-0482; 67877-719; 52076-6247; 0078-0594; 0054-0470; 49884-159; 0378-3097; 49884-158; 68254-6234; 65727-063; 49884-160; 70377-013; 71796-012; 49884-119; 0378-3098; 70225-1103; 52076-6253; 70377-010; 0078-0422; 0054-0497; 0078-0414; 0054-0471; 0378-0006; 0093-7767; 0078-0627; 52076-6234; 62227-013; 0093-7766; 0078-0628; 71052-559; 67877-720; 0378-0005; 65727-046; 49884-125; 0054-0472; 0054-0604; 0078-0566; 49884-283; 0378-0007; 67877-721; 67877-718; 51991-823; 0054-0481; 17404-1027; 0078-0417; 0078-0415; 0093-7768; 49884-127; 70377-011; 62227-018; 70377-012; 0054-0480; 62227-019; 51991-821; 51991-822; 0078-0567; 0378-3096; 51991-824
Synonyms Everolimus | SDZ RAD | RAD, SDZ | SDZ-RAD | 40-O-(2-hydroxyethyl)-rapamycin | RAD 001 | 001, RAD | RAD001 | Certican | Afinitor
Chemical Information
Molecular Formula C53H83NO14
CAS Registry Number 159351-69-6
SMILES CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O) C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000952%
Disturbance in attention19.21.02.002; 17.03.03.001--
Diverticulitis07.10.02.001; 11.01.07.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug eruption23.03.05.001; 08.01.06.015; 10.01.01.005--Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.0020.012772%
Dry skin23.03.03.0010.016786%
Dry throat22.02.05.004; 07.06.01.0050.001095%Not Available
Duodenal ulcer07.04.02.0020.001095%
Duodenitis07.08.03.0010.000730%Not Available
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia17.02.07.003; 07.14.03.0010.029558%
Dyskinesia17.01.02.006--
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.021895%
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.0040.006204%
Dyspnoea02.01.03.002; 22.02.01.0040.126260%
Dyspnoea at rest22.02.01.025; 02.01.03.0070.000730%Not Available
Dyspnoea exertional22.02.01.005; 02.01.03.0030.007663%Not Available
Dysuria20.02.02.0020.005474%
Ear disorder04.03.01.0010.000730%Not Available
Ear infection11.01.05.001; 04.03.01.0060.002189%Not Available
Ear pain04.03.01.0030.001825%
Eating disorder19.09.01.008; 14.03.01.0080.010947%Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 41 Pages